Professor Andrew Owen

Andrew Owen is a co-director of the Centre of Excellence in Long-acting Therapeutics (CELT) at the University of Liverpool. He is principal investigator for LONGEVITY, an international project funded by Unitaid that aims to translate long-acting medicines for malaria, tuberculosis, and Hepatitis C Virus.

Andrew also leads a modelling and simulation core and sits on the executive group for the NIH-funded Long-acting/Extended-release Antiretroviral resource Programme (LEAP). He is a Director and Chief Scientific Officer for Tandem Nano Ltd. and co-inventor of patents relating to drug delivery.

Since March 2020, he has been intensively engaged in evaluation of SARS-CoV-2 antiviral candidates.